Girao Tiago 4
4 · Immunovant, Inc. · Filed Apr 9, 2026
Research Summary
AI-generated summary of this filing
Immunovant (IMVT) CFO Tiago Girao Receives Equity Awards
What Happened Tiago Girao, Chief Financial Officer of Immunovant, was granted equity awards on April 7, 2026. The filing shows 64,968 restricted stock units (RSUs) and 94,002 derivative awards (options or option-like units) granted, each reported at $0.00 (awards, not open-market purchases). These are company compensation grants, not sales or purchases of existing shares.
Key Details
- Transaction date: 2026-04-07; Form 4 filed: 2026-04-09 (appears timely).
- Grant amounts: 64,968 RSUs (reported as Acquired) and 94,002 derivative awards (reported as Acquired).
- Reported price: $0.00 for both lines (typical for equity grants); see full filing for any option exercise/strike price details.
- Shares owned after transaction: not specified in the provided excerpt — check the full Form 4 for total beneficial ownership.
- Footnotes:
- F1 (RSUs): Vest 25% on April 1, 2027, then the balance in 12 successive substantially equal quarterly installments, subject to continued service.
- F2 (Options): Vest 25% on April 1, 2027, then the balance in 36 successive substantially equal monthly installments, subject to continued service.
Context These transactions are awards under the Issuer's 2019 Equity Incentive Plan and represent compensation tied to future vesting, not immediate purchases or sales. The RSUs convert to shares upon vesting; the derivative awards are option-type grants that vest over time. Because these are compensation grants, they do not by themselves indicate immediate insider buying or selling activity. For full details (including any exercise price, total holdings after the grant, and other disclosures), consult the complete Form 4 filing (Accession 0001764013-26-000032).
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-07+64,968→ 273,356 total - Award
Stock Option (right to buy)
[F2]2026-04-07+94,002→ 94,002 totalExercise: $24.61Exp: 2036-04-07→ Common Stock (94,002 underlying)
Footnotes (2)
- [F1]These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
- [F2]These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.